Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma

Fig. 6

Combination treatment with anti PD-1 antibody does not increase SD101 control of primary tumor growth, but decrease metastatic dissemination. A. Graphs show mean mOS69 tumor volume for treated (left panel) and untreated (right panel) lesions. Five to seven animals per group were used. A representative experiment is shown (out of 3 experiments performed). Multiple unpaired t tests, one per time points, were used for statistical analysis (on graphs only the last time point p values are shown). B. Graphs show the number (left panel) and lung area of lung metastases (righ panel) of mOS69 injected i.v. Lung metastases were counted by histological evaluation on serial lung Sects. (2 sections for each sample), stained with hematoxylin and eosin (H&E) in blind by two operators and metastatic area quantified using Leica Las Core software under a DM4B Leica microscope. Percentage of lung area occupied by metastases was measured as follows: (sum of areas of all metastatic lesions /total lung area) × 100. six animals per group were used. C. Representative histological images of lungs from control, SD101-treated and SD101 + anti-PD-1 receiving animals

Back to article page